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Abstract
Background: Significant biochemical changes are observed in glycosaminoglycans in squamous cell laryngeal
carcinoma. The most characteristics are in chondroitin/dermatan sulfate fine structure and proportion, which might
be due to differential expression of the enzymes involved in their biosynthesis. The aim of the present work was
the investigation in expressional and epigenetic level of the enzymes involved in chondroitin/dermatan sulfate
biosynthesis in laryngeal cancer.
Methods: Tissues subjected to total RNA and DNA isolation, and protein extraction. The techniques used in this
study were RT-PCR analysis, western blotting and methylation specific PCR.
Results: We identified that many enzymes were expressed in the cancerous specimens intensively. Dermatan
sulfate epimerase was expressed exclusively in the cancerous parts and in minor amounts in healthy tissues; in the
macroscopically normal samples it was not detected. Furthermore, chondroitin synthase I and chondroitin
polymerizing factor were strongly expressed in the cancerous parts compared to the corresponding normal tissues.
Sulfotransferases, like chondroitin 6 sulfotransferase 3, were highly expressed mainly in healthy specimens.
Conclusions: The study of the various chondroitin/dermatan synthesizing enzymes revealed that they were
differentially expressed in cancer, in human laryngeal cartilage, leading to specific chondroitin/dermatan structures
which contributed to proteoglycan formation with specific features. The expression of the examined enzymes
correlated with the glycosaminoglycan profile observed in previous studies.
Background
The chondroitin/dermatan sulfate fine chemical struc-
ture is altered in laryngeal carcinomas [1,2] as well as in
most cancers [3-5]. In healthy larynx, chondroitin/der-
matan sulfate (C-6 and C-4 sulfated) in the cartilaginous
parts is present in greater amounts compared to cancer.
Moreover, the decrease in cancer is more abrupt in C-6
sulfation; C-4 sulfation is diminished gradually to the
advanced stages of cancer. These alterations may be due
to differential biosynthesis of core protein precursors, to
differences in the substrates pool, and to differential
expression of the enzymes involved in chondroitin/der-
matan sulfate biosynthesis.
The chondroitin and dermatan sulfate synthesizing and
modifying enzymes are characterized [6-12]. Chondroitin
synthases (CHSY1, CHSY2 (CHPF) and CHSY3) and
chondroitin sulfate glucuronyltransferase (CSGlcA-T)
polymerize the glycosaminoglycan chains. The polymer
modifying enzymes include sulfotransferases (C4ST1,
D4ST1, C4ST2, C4ST3 and CHST3) and dermatan
sulfate epimerase (DSE). In a previous study, we demon-
strated that CHST3 and D4ST1 were expressed differen-
tially in colorectal cancer [4], thus leading to increased
C-6 sulfation in cancer compared to healthy tissues and
decreased C-4 sulfation in late stages.
The purpose of the present study was to examine the
expression of the various chondroitin/dermatan sulfate
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lage in healthy, macroscopically normal and cancerous
specimens by RT-PCR analysis and western blotting.
Furthermore, methylation specific PCR (MSP) was used
to find out if DNA methylation is a regulative mechan-
ism of their expression in laryngeal cancer.
Methods
Chemicals and biologic material
Each cartilaginous laryngeal tissue specimen (28 sam-
ples, 60 ± 11 y) of male patients with advanced cancer
stage (stages III and IV) was separated into normal and
cancerous part. Specimens of healthy donors (4 samples,
aged 50 ± 14 y) were also included in the study. The
study design was approved by the Ethical Committee of
the University Hospital of Patras and was in accordance
with the Helsinki Declaration of 1975, as revised in
1983.
Phosphate buffer saline (PBS) and phenylmethylsulfo-
nyl fluoride (PMSF) were obtained from Serva
(Darmstadt, Germany). Benzamidine hydrochloride, ε-
amino-n-caproic acid, Triton X-100, N-ethylmaleimide
and disodium EDTA were obtained from Sigma. RNA
extraction kit (Nucleospin RNA II) was from
Macherey-Nagel (Düren, Germany). PrimeScript™one
step RT-PCR kit and 100 bp DNA ladder were
obtained from TakaRa BIO INC (Ōtsu, Japan). Goat
antibodies against CHSY1 (N-13), CHSY2 (E-19),
CHSY3 (C-17) and C4ST1 (N-18) were purchased
from Santa Cruz Biotechnology, INC (Santa Cruz,
USA). Rabbit anti-goat IgG horseradish peroxidase
conjugated was from Chemicon (California, USA).
DNeasy Blood & Tissue Kit, RNAse A, EpiTect® Bisul-
fite kit and HotStarTaq DNA Polymerase were from
Qiagen. RNA extraction kit (Nucleospin RNA II) was
from Macherey-Nagel (Düren, Germany). ECL Western
Blotting Substrate was from Pierce biotechnology
(Rockford, USA). The gene specific primers were pur-
chased by Lieferschein (Germany). All other chemicals
used throughout the study were of the highest avail-
able grade.
RNA extraction and RT-PCR
RNA extraction, RT-PCR analysis and agarose gel elec-
trophoresis were performed essentially as described else-
where [4]. The specimens were pulverized in liquid
nitrogen and subjected to total RNA exctraction using
the Nucleospin extraction kit and treated with RNase-
free DNase to remove contaminating genomic DNA.
The primers used (illustrated in table 1) were designed
using a free software (PerlPrimer v1.1.14). Takara one
step RT-PCR kit was used to perform the analysis. The
conditions of RT-PCR were as previously [4]. RT-PCR
products were separated by gel electrophoresis on 2%
w/v agarose gel containing SYBR Gold stain to visualize
the bands under UV. The gels were then scanned and
the bands were analyzed densitometrically. Quantitative
differences between cDNA samples were normalized by
including GAPDH in all experiments.
DNA isolation and MSP
Tissue specimens were treated for DNA isolation with
DNeasy Blood & Tissue Kit. For complete bisulfite con-
version and cleanup of DNA for methylation analysis
the Epitect® Bisulfite kit was used. The processes were
performed as follows: The tissue specimens were pulver-
ized in liquid nitrogen and then incubated in proteinase
K solution at 56°C overnight. Then RNase A was added
to remove any contaminating RNA followed by a short
incubation (2 min) at 25°C. The isolated DNA was used
for the conversion of unmethylated C to U. Eight hun-
dred ng of total DNA was used to be converted by the
bisulfite reaction in a thermal cycler. The thermal cycler
conditions for the conversion were 3 successive steps of
denaturation and incubation. Each denaturation step
took place at 99°C for 5 min and each incubation step
at 60°C. The first incubation step was for 25 min, the
second for 1 h and 25 min and the third for 2 h and 55
min. One hundred ng of DNA was used for MSP. The
primers (illustrated in table 2) were constructed manu-
ally. The conditions for MSP were as follows: Taq poly-
merase was activated at 95°C for 15 min, followed by 35
amplification cycles and 10 min at 72°C. Each cycle con-
sisted of 3 steps which were as follows: For DSE, 94°C
for 30 s, 60°C for 30 s and 72°C for 1 min. For C4ST1,
Table 1 Nucleotide sequence of the primers used in
RT-PCR experiments
Type of primer Nucleotide sequence (5-3)
CHSY1-F AGTGTGTCTGGTCTTATGAGATGCA
CHSY1-R AGCTGTGGAGCCTGTACTGGTAG
CHPF-F GTCAGGACCCGCTACATCAG
CHPF-R CTCTCCGCCGATGAAGTCCT
CHSY3-F CGATGTCTACATCAAAGGTGACAAA
CHSY3-R GCTGGAAGTGGTTGAAAGAAGG
CSGlcAT-F AGAACAACTGCAGGCTCAGATCC
CSGlcAT-R AGAGTGTGGTGTGAAAGGAGCAG
CHST3-F CATATCAAGGGTCTCAGACAAGC
CHST3-R GTACAGGTCGCACAGGAAGAG
C4ST1-F AAGTATGTTGCACCCAGTCATGC
C4ST1-R TTCAAGCGGTTGTTGATTTCTGG
D4ST1-F ACTGGAAGCGGGTGATGAAGG
D4ST1-R AAATCGGACGTGAGGTGGTGC
DSE-F TGGTTGGTGAAAGATGCTCCT
DSE-R GTCCTTTGAAACCCTGGCAG
GAPDH-F TCAAGATCATCAGCAATGCCTCC
GAPDH-R AGTGAGCTTCCCGTTCAGC
Kalathas et al. Head & Neck Oncology 2010, 2:27
http://www.headandneckoncology.org/content/2/1/27
Page 2 of 894°C for 30 s, 52.5°C for 45 s and 72°C for 1 min.
Finally, for D4ST1, 94°C for 30 s, 58.5°C for 35 s and
72°C for 1 min. PCR products were separated by gel
electrophoresis on 3% w/v agarose gel containing SYBR
Gold stain to visualize the bands under UV. The gels
were then scanned.
Protein extraction-Western blotting
Parts of healthy, macroscopically normal and cancerous
tissues were used for the detection of chondroitin
synthases and chondroitin sulfate 4-sulfotransferase.
Each specimen was finely diced and the macromolecules
contained were sequentially extracted for 3X24 h peri-
ods at 4°C in the darkness with PBS (10 mM disodium
phosphate, 0.14 M NaCl, pH 7.4), 4 M GdnHCl-0.05 M
sodium acetate pH 5.8 and 4 M GdnHCl-0.05 M
sodium acetate-1% Triton X-100 pH 5.8, using 10 vols
of extraction buffer per g of tissue. A protease inhibitor
cocktail was also included [13]. The samples were there-
after subjected to western blotting as described [14].
Results
Chondroitin synthases and glucuronyltransferase
expression
CHSY1 gene expression in healthy tissues was about to
one twelfth of that of GAPDH (fig 1A). In pathologic
samples, increased expression was detected compared to
healthy, being 30% as indicated by RT-PCR experiments
(fig. 1A), and 10% from western blotting (fig. 2A). The
macroscopically normal samples expressed the enzyme
to a smaller extent compared to pathologic ones, being
about 30% as indicated by RT-PCR (fig. 1A). About simi-
lar results were obtained using western blotting, however
the expression found was higher (70%) (fig. 2A).
CHSY2 gene was the chondroitin synthase with the
highest expression in healthy tissues (1.25 times the
GAPDH levels), indicating its great importance in chon-
droitin/dermatan polymerization. A very clear decrease
of its expression was observed in patients’ specimens. Its
expression, in the pathologic samples, was about half
than that of the healthy specimens (P < 0.05), as indi-
cated by RT-PCR analysis (fig. 1B) and western blotting
(fig. 2B). Moreover, the pathologic samples, compared
to adjacent normal, expressed the enzyme 2 to 3 times
higher.
The healthy specimens expressed CHSY3 gene to the
one fifth compared to GAPDH gene. The specified
enzyme was expressed about in equal amounts between
macroscopically normal and pathologic samples, but
very low compared to healthy. Its decrease in cancer
was about 8 times (P < 0.05) as indicated by both
RT-PCR analysis and western blotting (fig. 1C, 2C).
The expression of CSGlcA-T gene was 7 times lower
than that of GAPDH gene in healthy tissues. Its expres-
sion was found to be increased in cancer in both normal
and pathologic samples, as indicated from RT-PCR
experiments (fig. 1D). The increase was more profound
in pathologic samples, being 50% and statistically signifi-
cant (P < 0.05).
Chondroitin sulfotransferases expression
CHST3 gene was expressed in healthy tissues about the
same levels as the GAPDH gene (fig. 3A). Its expression
was decreased in patients’ specimens to 50% compared
to healthy as indicated by RT-PCR analysis, being statis-
tically significant (P < 0.05). Moreover, the expression
was equal between the macroscopically normal and
pathologic samples.
C4ST1 gene expression was very low in healthy speci-
mens (20 times lower compared to the GAPDH gene),
and increased in patients’ specimens as indicated by
both RT-PCR and western blotting (fig. 3C,2D). Its
expression seemed to be controlled via methylation of a
CpG island, since hypomethylation of the gene was
observed in the pathologic samples compared to the
macroscopically normal samples (fig.4A).
D4ST1 gene was about equally expressed with the
GAPDH gene and possessed its highest expression in
the healthy tissues (fig. 3B). In cancer, its expression
was decreased 4 to 5 times and it was about equal
between normal and pathologic samples (fig. 3B). The
CpG island near the promoter region was fully
unmethylated therefore it did not affect the enzyme
expression (fig. 4C).
DSE expression
DSE gene was expressed in negligible amounts in the
healthy tissues (more than 50 times lower expression
Table 2 Nucleotide sequence of the primers used in the
MSP experiments.
Type of primer Nucleotide sequence (5-3)
DSE-UF GTGGAGGTGATGTTGGAGAGAAT
DSE-MF AGGCGACGTCGGAGAGAAC
DSE-UR AAACTACCCACCCAAAACTCCCA
DSE-MR TACCCGCCCGAAACTCCCG
D4ST-UF GGGTGGAGAGTGGTTGGGT
D4ST-MF GTGGAGAGCGGTCGGGC
D4ST-UR AATAACCAACTCCCAAACTACAACA
D4ST-MR CCGACTCCCGAACTACGACG
C4ST-UF TTAGATGGTGGTTGAGTTT
C4ST-MF TTAGACGGCGGTCGAGTTC
C4ST-UR AAAATATAATCACATCCAACTATTAACCA
C4ST-MR ATCGCGTCCAACTATTAACCG
The longer segments of the unmethylated primers are in boldface type and
differences between methylated/modified and ummethylated/modified
sequence are underlined underlined
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detected in the macroscopically normal samples, and the
highest levels of it were observed in the pathologic sam-
ples, as indicated by RT-PCR (fig. 3D), being about
10-times more compared to healthy. DSE expression
seemed to be controlled by methylation of the promoter
region in certain samples; the pathologic samples were
hypomethylated compared to the macroscopically nor-
mal (fig. 4B).
Discussion
We have studied the various chondroitin/dermatan poly-
merizing and modifying enzymes in healthy, macrosco-
pically normal and cancerous human laryngeal cartilage.
In previous studies [1], it was indicated that in the carti-
laginous parts the chondroitin/dermatan profile is inten-
sively altered in the advanced stages of cancer compared
to the healthy cartilage. Therefore, we examined the
chondroitin/dermatan polymerizing and modifying
enzymes as the major etiology of these alterations. The
extractability of the studied enzymes in PBS indicated
that a major part secreted from the cells. In previous
studies, the presence of such enzymes (CHSY1, D4ST1,
C4ST1) in the conditioned medium in cultured cells
was also identified [15].
The healthy laryngeal cartilage possesses great
amounts of chondroitin/dermatan sulfate which in can-
cer are decreased [1], but this was not the same for the
Figure 1 RT-PCR analysis of the chondroitin/dermatan synthesizing enzymes. A. CHSY1, B. CHPF, C. CHSY3 D. CSGlcA-T, in macroscopically
normal (N) and pathological (P) specimens. White boxes, healthy; grey boxes, macroscopically normal; black boxes, cancerous
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alterations were not similar for all enzymes studied.
CHSY3 and CHSY2 were decreased (fig. 1B, C and
fig. 2A, C), whereas CHSY1 and CSGlcAT were
increased (fig. 1A, D and fig. 2A). Since the decrease of
the former was very high compared to the increase of
the latter, the general decrease of CS/DS is explained.
The ratio of dermatan sulfate to chondroitin sulfate is
increased in cancer [2] and thus the relative increase of
dermatan sulfate should be attributed to DSE increased
expression observed in the present work. Dermatan
sulfate is considered as a glycosaminoglycan acting as a
tumor suppressor and thus DSE may be considered as a
tumor suppressor gene. Simultaneously, the D4ST1
decrease in cancer compared to healthy tissues may lead
to more aggressive cancers due to the increased chon-
droitin formation. It is noteworthy that D4ST1 is pivotal
for iduronic acid formation [16].
Chondroitin polymerizingf a c t o ra n dc h o n d r o i t i n
synthase III were decreased in cancer compared to
healthy tissues. In contrast, chondroitin synthase I is
expressed mainly in cancer. These results further explain
the obtained sulfation profile because CSA and mainly
CSB (the C-4 sulfated chondroitin and dermatan sulfate,
Figure 2 Western blot analysis in the sequential extracts. A. CHSY1 B. CHSY2 C. CHSY3 and D. C4ST1. 1. PBS 2. 4 M GdnHCl-0.05 M sodium
acetate and 3. 4 M GdnHCl-0.05 M sodium acetate-1% Triton X-100. Five microlitres were used for PBS extracts and fifty microlitres for both
others.
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Therefore, the C-4 sulfation is favored in cancer. CHPF
preferentially synthesizes C-6 chondroitin sulfate. It is
noteworthy that all chondroitin synthases prefer non-
sulfated and CSC substrates [6,9]. However, it has been
shown that chondroitin polymerization is achieved by
formation of complexes between the various chondroitin
synthases and CSGlcA-T [17].
C-6 sulfation is decreased dramatically by stage
whereas C-4 sulfation gradually. According to our study
CHST3 gene expression was decreased in cancer com-
pared to healthy tissues profoundly leading to C-6 sulfa-
tion decrease. D4ST1 gene expression was decreased,
whereas C4ST1 gene was expressed more in the cancer-
ous parts than in the macroscopically normal. Therefore,
C-4 sulfation in CS-disaccharides could be relatively
augmented in cancer but C-4 sulfation in DS-disacchar-
ides decreased, yielding to an overall gradual C-4 sulfa-
tion decrease. Moreover, C4ST1 augmentation could
lead to reduced C-6 sulfation in an indirect manner.
Data from other studies indicated that an additional
glycosaminoglycan-modifying enzyme was found to have
altered expression in cancer. D-glucuronyl C5 epimer-
ase, acting exclusively on heparin and heparan sulfate,
was found to be decreased in breast cancer [18]. On the
other hand, dermatan sulfate epimerase (DSE), accord-
ing to our and other studies [12], was increased. These
findings suggest that both epimerases are affected in
cancer leading to altered proteoglycan (both CS/DS and
HS containing) biosynthesis.
Figure 3 RT-PCR analysis of chondroitin/dermatan modifying enzymes. A. CHST3 B. D4ST1 C. C4ST1 and D. DSE. For details, see fig. 1.
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various proteoglycans, which is completed by the action
of the studied enzymes, is important because it will lead
to the deep comprehension of their role in cancer. More-
over, the examination of the regulatory mechanisms of
these genes will guide to the exact understanding of the
various pathways associated with cancer and thus will
contribute to more targeted and effective treatment.
Conclusions
The differential modification of the various glycosamino-
glycans during cancer reflected differential expression of
the enzymes involved in their biosynthesis. In our study,
the most clear observations in laryngeal cancer were the
significant decrease of CHSY3, CHST3 and D4ST1, and
the significant increase of DSE. DSE is responsible for the
epimerization of glucuronic acid in dermatan sulfate
chains, which in addition require D4ST1 for their sulfa-
tion. The differential expression of only these two
enzymes, which are highly responsible for the biosynthesis
of dermatan sulfate, a glycosaminoglycan with tumor-inhi-
bitory activity, indicates that a simple imbalance in
enzymes’ expression may affect tumor progression.
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